Jade Biosciences, Inc.
JBIO
$15.26
$0.040.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 14.82% | 19.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 24.20% | 27.66% | |||
| Operating Income | -24.20% | -27.66% | |||
| Income Before Tax | -26.60% | -26.61% | |||
| Income Tax Expenses | -72.41% | -- | |||
| Earnings from Continuing Operations | -26.42% | -26.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -26.42% | -26.84% | |||
| EBIT | -24.20% | -27.66% | |||
| EBITDA | -24.21% | -27.68% | |||
| EPS Basic | -15.77% | -2.72% | |||
| Normalized Basic EPS | -18.29% | 7.17% | |||
| EPS Diluted | -15.77% | -2.72% | |||
| Normalized Diluted EPS | -18.29% | 7.17% | |||
| Average Basic Shares Outstanding | 7.01% | 36.39% | |||
| Average Diluted Shares Outstanding | 7.01% | 36.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||